The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Antituberculosis drugs and hepatotoxicity
Abstract
Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such reactions during antituberculosis chemotherapy. Most of the hepatotoxic reactions are dose‐related; some are, however, caused by drug hypersensitivity. The immunogenetics of antituberculosis drug‐induced hepatotoxicity, especially inclusive of acetylaor phenotype polymorphism, have been increasingly unravelled. Other principal clinical risk factors for hepatotoxicity are old age, malnutrition, alcoholism, HIV infection, as well as chronic hepatitis B and C infections. Drug‐induced hepatic dysfunction usually occurs within the initial few weeks of the intensive phase of antituberculosis chemotherapy. Vigilant clinical (including patient education on symptoms of hepatitis) and biochemical monitoring are mandatory to improve the outcomes of patients with drug‐induced hepatotoxicity during antituberculosis chemotherapy. Some fluoroquinolones like ofloxacin/levofloxacin may have a role in constituting non‐hepatotoxic drug regimens for management of tuberculosis (TB) in the presence of hepatic dysfunction. Isoniazid administration is currently the standard therapy for latent TB infection. Rifamycins like rifampicin or rifapentine, alone or in combination with isoniazid, may also be considered as alternatives, pending accumulation of further clinical data. During treatment of latent TB infection, regular follow up is essential to ensure adherence to therapy and facilitate clinical monitoring for hepatic dysfunction. Monitoring of liver chemistry is also required for those patients at risk of drug‐induced hepatotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
(2016) · Pediatric Clinical Practice Guidelines & Policies · doi:10.1542/9781610020190-part06-targeted · Cited by 920
Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., & Menzies, D. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-626oc · Cited by 840
Treatment for tuberculosis, guidelines for national programmes
Gyselen, E. A. (1994) · Health Policy · doi:10.1016/0168-8510(94)90025-6 · Cited by 708
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998
Joint Tuberculosis Committee of the British Thoracic Society (1998) · Thorax · doi:10.1136/thx.53.7.536 · Cited by 527
Iuat (1982) · Bulletin of the World Health Organization · Cited by 515
Toxic Hepatitis with Isoniazid and Rifampin
Steele, M. A., Burk, R. F., & DesPrez, R. M. (1991) · Chest · doi:10.1378/chest.99.2.465 · Cited by 437
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Lai, S.-L., Yang, S.-Y., Chang, F.-Y., & Lee, S.-D. (2002) · Hepatology · doi:10.1053/jhep.2002.32102 · Cited by 432
Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced Hepatitis
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Chang, S.-C., Chiang, C.-H., Chang, F.-Y., & Lee, S.-D. (2003) · Hepatology · doi:10.1053/jhep.2003.50144 · Cited by 426
Whalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., Mugerwa, R. D., Ellner, J. J., Nsubuga, P., Vjecha, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371201 · Cited by 396
Schaberg, T., Rebhan, K., & Lode, H. (1996) · European Respiratory Journal · doi:10.1183/09031936.96.09102026 · Cited by 379
Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
De, K., Snider, D. E., & Caras, G. J. (1978) · PubMed · doi:10.1164/arrd.1978.117.6.991 · Cited by 368
Nolan, C. M., Goldberg, S. V., & Buskin, S. E. (1999) · JAMA · doi:10.1001/jama.281.11.1014 · Cited by 368
Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000
Joint Tuberculosis Committee of the British Thoracic Society (2000) · Thorax · doi:10.1136/thorax.55.11.887 · Cited by 366
Aguado, J. M., Herrero, J. A., Gavald??, J., Torre-Cisneros, J., Blanes, M., Ruf??, G., Moreno, A., Gurgu??, M., Hayek, M., & Lumbreras, C. (1997) · Transplantation · doi:10.1097/00007890-199705150-00015 · Cited by 338
Sharma, S. K., Balamurugan, A., Saha, P. K., Pandey, R. M., & Mehra, N. K. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2108091 · Cited by 336
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection: (548072006-001)
(2000) · PsycEXTRA Dataset · doi:10.1037/e548072006-001 · Cited by 322
Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318
Hong Kong Chest Service/Tuberculosis Research Centre, M. M. R. C. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.1.36 · Cited by 304
Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., Jollow, D. J., & Keiser, H. R. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518170 · Cited by 300
UNGO, J. R., JONES, D., ASHKIN, D., HOLLENDER, E. S., BERNSTEIN, D., ALBANESE, A. P., & PITCHENIK, A. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.9711039 · Cited by 292
Halsey, N. A., Coberly, J. S., Desormeaux, J., Losikoff, P., Atkinson, J., Moulton, L. H., Contave, M., Johnson, M., Davis, H., Geiter, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06532-x · Cited by 270
Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., Ito, M., Yamamoto, Y., Ogura, T., Maeda, K., et al. (2000) · PubMed · Cited by 251
Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.
Pande, J. N., Singh, S. P., Khilnani, G. C., Khilnani, S., & Tandon, R. K. (1996) · Thorax · doi:10.1136/thx.51.2.132 · Cited by 244
Isoniazid-Associated Hepatitis: Report of an Outbreak 1
Garibaldi, R. A., Drusin, R. E., Ferebee, S. H., & Gregg, M. B. (1972) · American Review of Respiratory Disease · doi:10.1164/arrd.1972.106.3.357 · Cited by 232
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
Wong, W.-M., Wu, P.-C., Yuen, M.-F., Cheng, C.-C., Yew, W.-W., Wong, P.-C., Tam, C.-M., Leung, C.-C., & Lai, C.-L. (2000) · Hepatology · doi:10.1002/hep.510310129 · Cited by 231
Self-citationEna, J., & Valls, V. (2005) · Clinical Infectious Diseases · doi:10.1086/427802 · Cited by 217
Jasmer, R. M., Saukkonen, J. J., Blumberg, H. M., Daley, C. L., Bernardo, J., Vittinghoff, E., King, M. D., Kawamura, L. M., Hopewell, P. C., & for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-8-200210150-00007 · Cited by 201
Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection
Blumberg, H. M. (2005) · JAMA · doi:10.1001/jama.293.22.2776 · Cited by 190
Roy, B., Chowdhury, A., Kundu, S., Santra, A., Dey, B., Chakraborty, M., & Majumder, P. P. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02585.x · Cited by 187
Adverse Effects of Antituberculosis Drugs
Girling, D. J. (1982) · Drugs · doi:10.2165/00003495-198223010-00003 · Cited by 182
Glassroth, J. L., Rf, J., Iseman, Hopewell, P. C., Jl, H., Goldberger, M., Godfrey‐Faussett, P., Fujiwara, P. I., Lobato, M. N., El‐Sadr, W., et al. (1999) · Cited by 180
Menzies, D., Dion, M.-J., Rabinovitch, B., Mannix, S., Brassard, P., & Schwartzman, K. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-478oc · Cited by 168
Liver injury during antituberculosis treatment: An 11-year study
Døssing, M., Wilcke, J. T., Askgaard, D. S., & Nybo, B. (1996) · Tubercle and Lung Disease · doi:10.1016/s0962-8479(96)90098-2 · Cited by 157
Parthasarathy, R., Sarma, G. R., Janardhanam, B., Ramachandran, P., Santha, T., Sivasubramanian, S., Somasundaram, P. R., & Tripathy, S. P. (1986) · Tubercle · doi:10.1016/0041-3879(86)90003-6 · Cited by 150
Schechter, M., Zajdenverg, R., Falco, G., Barnes, G. L., Faulhaber, J. C., Coberly, J. S., Moore, R. D., & Chaisson, R. E. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200512-1953oc · Cited by 144
The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.
Fernández‐Villar, A., SOPEÑA, B., Fernández-Villar, J., Vázquez-Gallardo, R., Ulloa, F., Leiro, V., Mosteiro, M., & Piñeiro, L. (2004) · PubMed · Cited by 126
Hepatotoxicity of Rifampin-Pyrazinamide and Isoniazid Preventive Therapy and Tuberculosis Treatment
van Hest, R., Baars, H., Kik, S. V., van Gerven, P., Trompenaars, M. E., Kalisvaart, N. A., Keizer, S. T., Borgdorff, M. W., Mensen, M., & Cobelens, F. G. J. (2004) · Clinical Infectious Diseases · doi:10.1086/422645 · Cited by 125
Incidence of Hepatotoxicity Due to Antitubercular Medicines and Assessment of Risk Factors
Shakya, R., Rao, B. S., & Shrestha, B. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d525 · Cited by 123
The management of anti-tuberculosis drug-induced hepatotoxicity.
Tahaoğlu, K., Ataç, G., Sevim, T., Tärün, T., Yazıcıoğlu, Ö. M., Horzum, G., Gemci, I., Ongel, A., Kapaklı, N., & Aksoy, E. (2001) · PubMed · Cited by 123
Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.
Teleman, M. D., Chee, C. B. E., Earnest, A., & Wang, Y. T. (2002) · PubMed · Cited by 111
WHO and the Europe Region of IUATLD Task Force of ERS, Migliori, G. B., Raviglione, M. C., Schaberg, T., Davies, P. D. O., Zellweger, J. P., Grzemska, M., Mihaescu, T., Clancy, L., & Casali, L. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d43.x · Cited by 105
Study of Oxidative-Stress in Isoniazid-Rifampicin Induced Hepatic Injury in Young Rats
Sodhi, C. P., Rana, S., Mehta, S. K., Vaiphei, K., Attari, S. S., & Mehta, S. K. (1997) · Drug and Chemical Toxicology · doi:10.3109/01480549709003881 · Cited by 105
Anti-tuberculosis medication and the liver: dangers and recommendations in management
Thompson, N., Caplin, M. E., Hamilton, M., Gillespie, S. H., Clarke, S. W., Burroughs, A. K., & McIntyre, N. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08081384 · Cited by 99
Durand, F., Bernuau, J., Pessayre, D., Samuel, D., Bélaïche, J., Degott, C., Bismuth, H., Belghiti, J., Erlinger, S., RUEFF, B., et al. (1995) · Hepatology · doi:10.1002/hep.1840210407 · Cited by 88
Isoniazid-rifampin-induced hepatitis in hepatitis B carriers
Wu, J., Lee, S., Yeh, P.-F., Chan, C., Wang, Y.-J., Huang, Y., Tsai, Y., Lee, P.-Y., Ting, L., & Lo, K. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90846-s · Cited by 87
Nolan, C. M., Sandblom, R. E., Thummel, K. E., Slattery, J. T., & Nelson, S. D. (1994) · CHEST Journal · doi:10.1378/chest.105.2.408 · Cited by 86
Meyers, B. R., Papanicolaou, G. A., Sheiner, P. A., Emre, S., & Miller, C. M. (2000) · Transplantation · doi:10.1097/00007890-200001150-00013 · Cited by 83
Gurumurthy, P., Krishnamurthy, M. S., Nazareth, O., Parthasarathy, R., Sarma, G. R., Somasundaram, P. R., Tripathy, S. P., & Ellard, G. A. (1984) · PubMed · doi:10.1164/arrd.1984.129.1.58 · Cited by 81
Antituberculosis treatment-induced hepatotoxicity: role of predictive factors
Singh, J., Arora, A., Garg, P. K., Thakur, V. S., Pande, J. N., & Tandon, R. K. (1995) · Postgraduate Medical Journal · doi:10.1136/pgmj.71.836.359 · Cited by 76
TUBERCULOSIS IN RENAL TRANSPLANT RECIPIENTS1
Sayıner, A., Ece, T., Duman, S., et al. (1999) · Transplantation · doi:10.1097/00007890-199911150-00009 · Cited by 69
Severe hepatotoxicity due to anti-tuberculosis drugs in Spain.
Tost, J. R., Vidal, R., Caylà, J. A., Diaz-Cabanela, D., Jiménez, A., & Broquetas, J. M. (2005) · PubMed · Cited by 66
Saigal, S., Agarwal, S. R., Nandeesh, H. P., & Sarin, S. K. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02570.x · Cited by 62
Leung, C. C., Law, W. S., Chang, K. C., Tam, C. M., Yew, W. W., Chan, C. K., & Wong, M. (2003) · CHEST Journal · doi:10.1378/chest.124.6.2112 · Cited by 43
Self-citationHONGKONGCHESTSERVICEBRITISHME (1981) · The Lancet · doi:10.1016/s0140-6736(81)90057-x · Cited by 42
Analysis of Rifapentine for Preventive Therapy in the Cornell Mouse Model of Latent Tuberculosis
Miyazaki, E., Chaisson, R. E., & Bishai, W. R. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2126 · Cited by 41
Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients.
La, O., Jacob, L., Gm, C., Tp, L., Ben-Zvi, J. S., Donelson, S. S., & Felton, C. P. (1995) · PubMed · Cited by 41
Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation
Farrell, F. J., Keeffe, E. B., Man, K. M., Imperial, J. C., & Esquivel, C. O. (1994) · Digestive Diseases and Sciences · doi:10.1007/bf02090381 · Cited by 32
Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
Schreiber, J., Zissel, G., Greinert, U., et al. (1999) · PubMed · Cited by 29
Various clinical presentations of tuberculosis in heart transplant recipients
Chou, N., Liu, L.-T., Ko, W.-J., Hsu, R.-B., Chen, Y., Yu, H., Chi, N.-H., Chang, S., & Wang, S. (2004) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.08.114 · Cited by 15
Collins, C., & Starmer, G. A. (1995) · Drug and Alcohol Review · doi:10.1080/09595239500185071 · Cited by 11
Cited by
Thwaites, G., Fisher, M., Hemingway, C., Scott, G., Solomon, T., & Innes, J. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.06.011 · Cited by 666
Ayeleso, T., Matumba, M., & Mukwevho, E. (2017) · Molecules · doi:10.3390/molecules22111915 · Cited by 333
Lange, C., Abubakar, I., Alffenaar, J.-W. C., Bothamley, G., Caminero, J. A., Carvalho, A. C. C., Chang, K.-C., Codecasa, L., Correia, A., Crudu, V., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00188313 · Cited by 310
Self-citationThe risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement
Bumbacea, D., Arend, S. M., Eyuboglu, F., Fishman, J. A., Goletti, D., Ison, M. G., Jones, C. E., Kampmann, B., Kotton, C. N., Lange, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00000712 · Cited by 264
Abbara, A., Chitty, S., Roe, J. K., Ghani, R., Collin, S. M., Ritchie, A., Kon, O. M., Dzvova, J., Davidson, H., Edwards, T. E., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2330-z · Cited by 100
Metadata
- Authors
- YEW, W. W., & LEUNG, C. C.
- Venue
- Respirology
- Publisher
- Wiley
- Published
- 2006-10-16
- Volume
- 11
- Issue
- 6
- Pages
- 699-707
- ISSN
- 1323-7799 (ISSN-L)
- 1440-1843
- OpenAlex
- W2123575911
- Cited by
- 256
- References
- 63
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.